Market Authorization granted to Prevtec Microbia for Coliprotec® F4/F18 in Canada


Prevtec Microbia is pleased to announce that it has been granted a market authorization by the Canadian Food Inspection Agency’s Canadian Centre for Veterinary Biologics (CFIA-CCVB) to commercialize its Coliprotec® F4/F18 vaccine. Coliprotec® F4/F18 is an oral live bacterial vaccine for the active immunization of piglets of at least 18 days of age against Post-Weaning Diarrhea caused by F4-positive and F18-positive enterotoxigenic and edema disease caused by F18-positive shigatoxin-producing E. coli. Coliprotec® F4/F18 was developed by Prevtec Microbia and will be distributed by Elanco Animal Health in Canada.

Coliprotec F4F18_coul

< View all news